Table 4.
Cilostazol | Control | p value | |||
---|---|---|---|---|---|
Total cholesterol (mg/dl) | 0.557 | ||||
Baseline | 188.20 | ±41.34 | 190.42 | ±37.59 | |
Follow-up | 169.11 | ±35.53 | 167.69 | ±35.30 | |
Mean change | –21.53 | ±43.01 | –23.17 | ±48.95 | |
HDL cholesterol (mg/dl) | 0.006 | ||||
Baseline | 41.46 | ±11.00 | 40.51 | ±11.02 | |
Follow-up | 53.86 | ±15.00 | 46.95 | ±12.95 | |
Mean change | 11.50 | ±15.59 | 6.29 | ±10.82 | |
Triglyceride (mg/dl) | 0.212 | ||||
Baseline | 141.91 | ±70.43 | 149.37 | ±106.87 | |
Follow-up | 113.63 | ±54.23 | 141.76 | ±77.92 | |
Mean change | –29.85 | ±65.23 | –9.94 | ±105.99 | |
LDL cholesterol (mg/dl) | 0.838 | ||||
Baseline | 117.40 | ±35.68 | 118.08 | ±33.82 | |
Follow-up | 97.24 | ±31.40 | 100.83 | ±31.83 | |
Mean change | –21.00 | ±35.07 | –17.19 | ±42.56 | |
HbA1c (%) | 0.750 | ||||
Baseline | 6.05 | ±1.23 | 6.22 | ±1.37 | |
Follow-up | 6.31 | ±0.93 | 6.51 | ±1.38 | |
Mean change | 0.13 | ±1.18 | 0.19 | ±1.21 |
p value by two-way ANOVA adjusted for administration of statins